LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 6 of total 6

Search options

  1. Article ; Online: Breaking Barriers: Addressing Issues of Inequality in Trial Enrollment and Clinical Outcomes for Patients With Kidney and Bladder Cancer.

    Hoffman-Censits, Jeannie / Kanesvaran, Ravindran / Bangs, Rick / Fashoyin-Aje, Lola / Weinstock, Chana

    American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting

    2021  Volume 41, Page(s) e174–e181

    Abstract: Despite recent treatment advances, kidney and bladder cancer cases have continued to rise in both incidence and mortality over the last few decades. Not every demographic subgroup of patients diagnosed with these cancers has an equivalent outcome. Women ... ...

    Abstract Despite recent treatment advances, kidney and bladder cancer cases have continued to rise in both incidence and mortality over the last few decades. Not every demographic subgroup of patients diagnosed with these cancers has an equivalent outcome. Women diagnosed with bladder cancer have worse overall survival than men diagnosed with bladder cancer. Older adults with muscle-invasive bladder cancer have worse cancer-specific outcomes than do younger patients. Black patients diagnosed with kidney and bladder cancers appear to have worse overall survival than White patients diagnosed with these cancers. Although these differences in outcomes are likely multifactorial, in many cases they may be based on modifiable approaches to screening, diagnosing, and treating patients. We explore various causes of these differences in outcomes between patients and address patient engagement strategies and avenues to effect change. In 2021, equity in cancer and cancer care delivery has a more prominent place in the hierarchy of the continuum of medicine. Continued focus on this topic is critical, with clear accountabilities established and barriers to best care for patients eliminated.
    MeSH term(s) African Americans ; Clinical Trials as Topic ; European Continental Ancestry Group ; Female ; Humans ; Incidence ; Kidney Neoplasms/diagnosis ; Kidney Neoplasms/epidemiology ; Kidney Neoplasms/therapy ; Male ; Treatment Outcome ; Urinary Bladder Neoplasms/diagnosis ; Urinary Bladder Neoplasms/epidemiology ; Urinary Bladder Neoplasms/therapy
    Language English
    Publishing date 2021-06-01
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2431126-1
    ISSN 1548-8756 ; 1548-8748
    ISSN (online) 1548-8756
    ISSN 1548-8748
    DOI 10.1200/EDBK_320273
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article: Penile sarcomatoid urothelial carcinoma: A case report.

    Wang, Shirley / Metcalf, Meredith / Hoffman-Censits, Jeannie / Bivalacqua, Trinity / Patel, Sunil H

    Urology case reports

    2021  Volume 38, Page(s) 101706

    Abstract: A 74-year-old man with a penile mass was diagnosed with sarcomatoid urothelial carcinoma. Further workup did not show any other lesions or metastases. He was treated with a total penectomy, bilateral inguinal lymph node dissection, and pelvic ... ...

    Abstract A 74-year-old man with a penile mass was diagnosed with sarcomatoid urothelial carcinoma. Further workup did not show any other lesions or metastases. He was treated with a total penectomy, bilateral inguinal lymph node dissection, and pelvic lymphadenectomy. Following surgery, he received six cycles of cisplatin and gemcitabine. Sarcomatoid carcinoma and carcinosarcoma of the urethra are rare; six prior cases have been reported in the literature, with this being the first urothelial with sarcomatoid component. Survival in patients with sarcomatoid carcinoma or carcinosarcoma of the urinary tract is poor, with the limited data supporting a multimodal approach to improve survival.
    Language English
    Publishing date 2021-05-07
    Publishing country United States
    Document type Case Reports
    ZDB-ID 2745459-9
    ISSN 2214-4420
    ISSN 2214-4420
    DOI 10.1016/j.eucr.2021.101706
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Identification of Lineage-specific Transcriptional Factor-defined Molecular Subtypes in Small Cell Bladder Cancer.

    Feng, Mingxiao / Matoso, Andres / Epstein, Gabriel / Fong, Megan / Park, Yong Hyun / Gabrielson, Andrew / Patel, Sunil / Czerniak, Bagdan / Compérat, Eva / Hoffman-Censits, Jeannie / Kates, Max / Kim, Seungchan / McConkey, David / Choi, Woonyoung

    European urology

    2023  

    Abstract: Small cell/neuroendocrine bladder cancers (SCBCs) are rare and highly aggressive tumors that are associated with poor clinical outcomes. We discovered that lineage-specific transcription factors (ASCL1, NEUROD1, and POU2F3) defined three SCBC molecular ... ...

    Abstract Small cell/neuroendocrine bladder cancers (SCBCs) are rare and highly aggressive tumors that are associated with poor clinical outcomes. We discovered that lineage-specific transcription factors (ASCL1, NEUROD1, and POU2F3) defined three SCBC molecular subtypes that resemble well-characterized subtypes in small cell lung cancer. The subtypes expressed various levels of neuroendocrine (NE) markers and distinct downstream transcriptional targets. Specifically, the ASCL1 and NEUROD1 subtypes had high NE marker expression and were enriched with different downstream regulators of the NE phenotype (FOXA2 and HES6, respectively). ASCL1 was also associated with the expression of delta-like ligands that control oncogenic Notch signaling. POU2F3, a master regulator of the NE low subtype, targeted TRPM5, SOX9, and CHAT. We also observed an inverse association between NE marker expression and immune signatures associated with sensitivity to immune checkpoint blockade, and the ASCL1 subtype had distinct targets for clinically available antibody-drug conjugates. These findings provide new insight into molecular heterogeneity in SCBCs with implications for the development of new treatment regimens. PATIENT SUMMARY: We investigated the levels of different proteins in a specific type of bladder cancer (small cell/neuroendocrine; SCBC). We could identify three distinct subtypes of SCBC with similarity to small cell/neuroendocrine cancers in other tissues. The results may help in identifying new treatment approaches for this type of bladder cancer.
    Language English
    Publishing date 2023-06-27
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 193790-x
    ISSN 1873-7560 ; 1421-993X ; 0302-2838
    ISSN (online) 1873-7560 ; 1421-993X
    ISSN 0302-2838
    DOI 10.1016/j.eururo.2023.05.023
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Reply to Kentaro Inamura's Letter to the Editor re: Mingxiao Feng, Andres Matoso, Gabriel Epstein, et al. Identification of Lineage-specific Transcriptional Factor-defined Molecular Subtypes in Small Cell Bladder Cancer. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2023.05.023.

    Feng, Mingxiao / Matoso, Andres / Epstein, Gabriel / Fong, Megan / Park, Yong Hyun / Gabrielson, Andrew / Patel, Sunil / Czerniak, Bagdan / Compérat, Eva / Hoffman-Censits, Jeannie / Kates, Max / Kim, Seungchan / McConkey, David / Choi, Woonyoung

    European urology

    2023  Volume 85, Issue 4, Page(s) e122–e123

    MeSH term(s) Humans ; Urinary Bladder Neoplasms/genetics
    Language English
    Publishing date 2023-09-27
    Publishing country Switzerland
    Document type Letter
    ZDB-ID 193790-x
    ISSN 1873-7560 ; 1421-993X ; 0302-2838
    ISSN (online) 1873-7560 ; 1421-993X
    ISSN 0302-2838
    DOI 10.1016/j.eururo.2023.08.030
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Clinicopathologic and Survival After Cystectomy Outcomes in Squamous Cell Carcinoma of the Bladder.

    Agrawal, Pranjal / Rostom, Mary / Alam, Ridwan / Florissi, Isabella / Biles, Michael / Rodriguez, Katherine / Hahn, Noah M / Johnson, Burles A / Matoso, Andres / Smith, Armine / Bivalacqua, Trinity J / Kates, Max / Hoffman-Censits, Jeannie / Patel, Sunil H

    Clinical genitourinary cancer

    2023  Volume 21, Issue 6, Page(s) 631–638.e1

    Abstract: Background: Squamous cell carcinoma of the bladder (SqCC) is a rare disease with limited management data. Thus, we sought to characterize the clinicopathologic and survival outcomes amongst patients with SqCC and explore the association of squamous ... ...

    Abstract Background: Squamous cell carcinoma of the bladder (SqCC) is a rare disease with limited management data. Thus, we sought to characterize the clinicopathologic and survival outcomes amongst patients with SqCC and explore the association of squamous differentiation within urothelial carcinoma (UC w/Squam), as compared to muscle invasive pure UC.
    Methods: We conducted a single-center retrospective cohort study of patients, stratified by histology, who underwent cystectomy for MIBC. Baseline clinicopathologic characteristics were compared, and overall survival was assessed using Kaplan-Meier method.
    Results: We identified 1,034 patients; 37 (3.58%) with SqCC histology, 908 (87.81%) with UC histology, and 89 (8.61%) with UC w/ Squam histology. Among SqCC patients, a higher proportion were Black and similarly a higher proportion were women; amongst patients with UC w/ Squam a higher proportion had lower BMI; and amongst patients with UC a higher proportion had lower clinical (c) T, cN, pathological (p) T, and pN stages. Patients presenting with UC were more likely to receive intravesical therapy; patients presenting with SqCC were less likely to receive neoadjuvant chemotherapy (NAC). Adjuvant chemotherapy rates were similar. With post-hoc Bonferroni analysis, overall survival, cancer-specific survival, and recurrence-free survival were significantly worse for the UC w/ Squam cohort.
    Conclusions: UC w/ Squam histology was associated with worse survival outcomes after cystectomy for muscle invasive bladder cancer compared to UC. Our results suggest that UC w/ Squam is associated with more advanced disease compared to UC, warranting further prospective work on consideration of combination therapies for patients with this disease state.
    MeSH term(s) Humans ; Female ; Male ; Urinary Bladder Neoplasms/pathology ; Carcinoma, Transitional Cell/pathology ; Urinary Bladder/pathology ; Cystectomy/methods ; Retrospective Studies ; Carcinoma, Squamous Cell/surgery ; Neoadjuvant Therapy
    Language English
    Publishing date 2023-05-30
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2225121-2
    ISSN 1938-0682 ; 1558-7673
    ISSN (online) 1938-0682
    ISSN 1558-7673
    DOI 10.1016/j.clgc.2023.05.019
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: First Report of NRG Oncology/Radiation Therapy Oncology Group 0622: A Phase 2 Trial of Samarium-153 Followed by Salvage Prostatic Fossa Irradiation in High-Risk Clinically Nonmetastatic Prostate Cancer After Radical Prostatectomy.

    Valicenti, Richard K / Pugh, Stephanie L / Trabulsi, Edouard J / Sartor, Oliver / Ko, Eric C / Girvigian, Michael R / Rosenthal, Seth A / Shaves, Mark E / Hoffman-Censits, Jeannie H / Schallenkamp, John / Sandler, Howard M

    International journal of radiation oncology, biology, physics

    2017  Volume 100, Issue 3, Page(s) 695–701

    Abstract: Purpose: To investigate the utility of : Patients and methods: Trial NRG Oncology RTOG 0622 is a single-arm phase 2 trial that enrolled men with pT2-T4, N0-1, M0 prostate cancer status post radical prostatectomy, who meet at least 1 of these ... ...

    Abstract Purpose: To investigate the utility of
    Patients and methods: Trial NRG Oncology RTOG 0622 is a single-arm phase 2 trial that enrolled men with pT2-T4, N0-1, M0 prostate cancer status post radical prostatectomy, who meet at least 1 of these biochemical failure criteria: (1) prostate-specific antigen (PSA) > 1.0 ng/mL; (2) PSA > 0.2 ng/mL if Gleason score 9 to 10; or (3) PSA > 0.2 ng/mL if N1. Patients received
    Results: A total of 60 enrolled eligible patients were included in this analysis. Median follow-up was 3.97 years. A PSA response was achieved in 7 of 52 evaluable patients (13.5%), compared with the 25% hypothesized. The 2-year freedom from progression rate was 25.5% (95% confidence interval 14.4%-36.7%), and the biochemical failure rate was 64.4% (95% CI 50.5%-75.2%). Samarium-153 was well tolerated, with 16 (of 60) grade 3 to 4 hematologic AEs and no grade 5 hematologic AEs. Radiation therapy was also well tolerated, with no grade 3 to 5 acute radiation therapy-related AEs and 1 grade 3 to 4 and no grade 5 late radiation therapy-related AEs.
    Conclusions: Trial NRG Oncology RTOG 0622 did not meet its primary endpoint of PSA response, although the regimen of
    MeSH term(s) Aged ; Aged, 80 and over ; Humans ; Male ; Middle Aged ; Neoplasm Grading ; Organometallic Compounds/adverse effects ; Organometallic Compounds/therapeutic use ; Organophosphorus Compounds/adverse effects ; Organophosphorus Compounds/therapeutic use ; Prostate-Specific Antigen/blood ; Prostatectomy ; Prostatic Neoplasms/blood ; Prostatic Neoplasms/pathology ; Prostatic Neoplasms/radiotherapy ; Prostatic Neoplasms/surgery ; Salvage Therapy/methods ; Treatment Failure
    Chemical Substances Organometallic Compounds ; Organophosphorus Compounds ; samarium Sm-153 lexidronam (745X144DZY) ; Prostate-Specific Antigen (EC 3.4.21.77)
    Language English
    Publishing date 2017-11-21
    Publishing country United States
    Document type Clinical Trial, Phase II ; Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
    ZDB-ID 197614-x
    ISSN 1879-355X ; 0360-3016
    ISSN (online) 1879-355X
    ISSN 0360-3016
    DOI 10.1016/j.ijrobp.2017.11.024
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top